Muscular Dystrophy, Duchenne

• 

  Subject Areas on Research

  • Acute heart failure during spinal surgery in a boy with Duchenne muscular dystrophy. 
  • Airway clearance in Duchenne muscular dystrophy. 
  • Ataluren treatment of patients with nonsense mutation dystrophinopathy. 
  • Clinical and genetic characterization of manifesting carriers of DMD mutations. 
  • Commentary on "Progression of Ankle Plantarflexion Contractures and Functional Decline in Duchenne Muscular Dystrophy: Implications for Physical Therapy Management". 
  • Commentary on "Supported Standing in Boys With Duchenne Muscular Dystrophy". 
  • Comparison of magnetic resonance feature tracking for strain calculation with harmonic phase imaging analysis. 
  • Comparison of right and left ventricular function and size in Duchenne muscular dystrophy. 
  • Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. 
  • Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. 
  • Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. 
  • Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. 
  • Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. 
  • Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. 
  • Duchenne muscular dystrophy and steroids: pharmacologic treatment in the absence of effective gene therapy. 
  • Dystrophin immunity in Duchenne's muscular dystrophy. 
  • Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. 
  • Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance. 
  • Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. 
  • Exercise and Duchenne muscular dystrophy: where we have been and where we need to go. 
  • Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy. 
  • Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy. 
  • Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. 
  • In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. 
  • Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy. 
  • Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. 
  • Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. 
  • Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. 
  • Molecular characterization of co-occurring Duchenne muscular dystrophy and X-linked oculo-facio-cardio-dental syndrome in a girl. 
  • Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. 
  • Non-invasive MRI and spectroscopy of mdx mice reveal temporal changes in dystrophic muscle imaging and in energy deficits. 
  • Patterns of left ventricular remodeling in patients with Duchenne Muscular Dystrophy: a cardiac MRI study of ventricular geometry, global function, and strain. 
  • Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. 
  • Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. 
  • Physiology of nitric oxide in skeletal muscle. 
  • Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. 
  • Presence of mechanical dyssynchrony in Duchenne muscular dystrophy. 
  • Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function. 
  • Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. 
  • Regional circumferential strain is a biomarker for disease severity in duchenne muscular dystrophy heart disease: a cross-sectional study. 
  • Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. 
  • Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. 
  • Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy. 
  • Suppression of revertant fibers in mdx mice by expression of a functional dystrophin. 
  • The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. 
  • The respiratory management of patients with duchenne muscular dystrophy: a DMD care considerations working group specialty article. 
  • The role of corticosteroids in Duchenne muscular dystrophy: a review for the anesthetist. 
  • Ultra-widefield imaging of Duchenne muscular dystrophy-associated proliferative retinal vasculopathy improved with panretinal laser photocoagulation alone. 
• 

  Keywords of People

  • Case, Laura Elizabeth, Assistant Professor of Orthopaedic Surgery, Orthopaedics, Physical Therapy